Addition of Infliximab to Standard Acute Graft-versus-Host Disease Prophylaxis Following Allogeneic Peripheral Blood Cell Transplantation

Infliximab, a chimeric monoclonal antibody against tumor necrosis factor-α, has shown activity against steroid refractory acute graft-versus-host disease (GVHD). We conducted a prospective trial of infliximab for the prophylaxis of acute GVHD. Patients older than 20 years undergoing myeloablative al...

Full description

Saved in:
Bibliographic Details
Main Authors: Hamadani, Mehdi, Hofmeister, Craig C., Jansak, Buffy, Phillips, Gary, Elder, Patrick, Blum, William, Penza, Sam, Lin, Thomas S., Klisovic, Rebecca, Marcucci, Guido, Farag, Sherif S., Devine, Steven M.
Format: Artigo
Language:Inglês
Published: 2008
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4100722/
https://ncbi.nlm.nih.gov/pubmed/18541197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2008.04.006
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items